Compare Recursion Pharmaceuticals Inc (RXRX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Synchrony Financial — how do they compare? Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B), while Synchrony Financial trades at $73.83 (market cap $23.40B). The key difference: Synchrony Financial is far larger — about 10.1× Recursion Pharmaceuticals Inc's market cap, and Synchrony Financial pays a 1.89% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Synchrony Financial for 28 Days on average.
| RXRX | SYF | |
|---|---|---|
Market Cap | $2.31B | $23.40B |
Volume | 40,478,768 | 2,108,179 |
Sector | Health | Financials |
52-Week High | $6.79 | $88.47 |
52-Week Low | $2.84 | $63.78 |
Typical Hold Time | 22 Days | 28 Days |
Enterprise Value | $1.83B | $23.64B |
Dividend Yield | — | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
SYF trades at $71.93, down 0.32% on the day, with a bearish technical signal from moving averages. The stock is valued attractively with a P/E of 7.38 and P/S of 1.68, supported by strong profitability including a 23.4% net income margin and 22.23% ROE. Recent earnings have consistently beaten estimates, and the company is expanding through partnerships like the Vetspire tie-up and OpenAI collaboration to enhance its digital payment solutions.
The outlook remains positive given the low valuation, high profitability, and strategic growth initiatives. Key risks include potential credit quality deterioration amid economic uncertainty and heavy investing cash outflows. Analyst consensus is bullish with a $88.18 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
